Tradestie Institutional Equity Comparison Engine

MLTX vs INVA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INVA Overall Edge

INVA Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Innoviva, Inc. Common Stock (INVA) driven by superior Valuation, Growth & Margin, Options & Structure while MLTX counters with relative strength in Momentum & Technical. Fundamentally, MLTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus INVA at 8.8x Forward P/E and 39.5% operating margin (-1.6% YoY). In options structure, MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against INVA sits in UNCLASSIFIED (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner INVA
MLTX N/M vs INVA 8.8x Fwd P/E
Growth & Margin Winner INVA
Op Margin 0.0% vs 39.5% ยท YoY +0.0% vs -1.6%
Momentum & Technical Winner MLTX
1Y -5.7% vs -16.3% ยท 52W Pos 17% vs 2%
Options & Structure Winner INVA
BREAKDOWN (7th %ile IV) vs UNCLASSIFIED (4th %ile IV)
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
1M Return +24.08%
1Y Return -5.65%
Forward P/E N/M
Unified AI Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
INVA NASDAQ
Innoviva, Inc. Common Stock
Pharmaceutical Preparations
$18.59
-2.34% 1D
Market Cap $1.3B
1M Return -10.56%
1Y Return -16.28%
Forward P/E 8.8x
Unified AI Score
48.9 / 100 HOLD
Tech 39.0 Fund 59.0 Flow 66.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MLTX -5.65% INVA -16.28% Spread: +10.63 pp (MLTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MLTX TTM Op. Margin: 0.0% INVA TTM Op. Margin: 39.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs INVA. Trailing 12-month operating profitability (MLTX 0.0% vs INVA 39.5%) and valuation multiples (MLTX N/M vs INVA 8.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MLTX (2) vs INVA (8)
Institutional Metric MLTX INVA Criterion Row Winner
Market Capitalization Scale $1.1B $1.3B Larger Scale INVA
Trailing P/E Ratio Valuation N/M 8.1x Lower Multiple INVA
Forward P/E Ratio Valuation N/M 8.8x Lower Multiple INVA
Revenue Growth (YoY) Growth +0.0% -1.6% Higher Growth MLTX
Operating Margin (TTM) Profitability 0.0% 39.5% Higher Margin INVA
Net Profit Margin Profitability 0.0% 44.1% Higher Margin INVA
Return on Equity (ROE) Capital Efficiency -81.5% 18.0% Higher ROE INVA
52-Week Range Position Momentum 17% ($9โ€“$23) 2% ($18โ€“$25) Stronger Trend MLTX
Beta / 30D Volatility Risk Regime 1.61ฮฒ ยท 90% Vol 0.32ฮฒ ยท 37% Vol Lower Realized Risk INVA
Unified Institutional Score Composite Signal 38.3 / 100 (SELL) 48.9 / 100 (HOLD) Higher Composite INVA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MLTX vs INVA Buy Guide
MLTX BREAKDOWN
103d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live MLTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INVA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live INVA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MLTX nor INVA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.